Aperio Group LLC boosted its position in shares of Dr.Reddy’s Laboratories Ltd (NYSE:RDY) by 12.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 236,318 shares of the company’s stock after purchasing an additional 25,673 shares during the period. Aperio Group LLC’s holdings in Dr.Reddy’s Laboratories were worth $8,177,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. NumerixS Investment Technologies Inc lifted its holdings in Dr.Reddy’s Laboratories by 115.0% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 4,300 shares of the company’s stock valued at $140,000 after purchasing an additional 2,300 shares during the last quarter. Krane Funds Advisors LLC lifted its holdings in Dr.Reddy’s Laboratories by 818.6% during the 2nd quarter. Krane Funds Advisors LLC now owns 4,703 shares of the company’s stock valued at $329,000 after purchasing an additional 4,191 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Dr.Reddy’s Laboratories during the 1st quarter valued at about $214,000. Capital Fund Management S.A. bought a new position in Dr.Reddy’s Laboratories during the 2nd quarter valued at about $225,000. Finally, Verition Fund Management LLC bought a new position in Dr.Reddy’s Laboratories during the 2nd quarter valued at about $309,000. 12.24% of the stock is owned by hedge funds and other institutional investors.

Several brokerages recently issued reports on RDY. ValuEngine raised shares of Dr.Reddy’s Laboratories from a “sell” rating to a “hold” rating in a report on Friday, October 12th. Zacks Investment Research raised shares of Dr.Reddy’s Laboratories from a “hold” rating to a “strong-buy” rating and set a $37.00 target price for the company in a research note on Friday, August 17th.

Shares of NYSE RDY opened at $33.81 on Monday. Dr.Reddy’s Laboratories Ltd has a 1-year low of $28.13 and a 1-year high of $39.96. The stock has a market capitalization of $5.61 billion, a price-to-earnings ratio of 33.48 and a beta of 0.13. The company has a quick ratio of 1.19, a current ratio of 1.64 and a debt-to-equity ratio of 0.20.

Dr.Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Thursday, July 26th. The company reported $0.40 earnings per share for the quarter. Dr.Reddy’s Laboratories had a net margin of 9.41% and a return on equity of 11.74%. The company had revenue of $543.00 million during the quarter, compared to the consensus estimate of $542.20 million. On average, equities research analysts anticipate that Dr.Reddy’s Laboratories Ltd will post 1.33 earnings per share for the current year.

Dr.Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Featured Story: Cash Flow Analysis in Stock Selection

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr.Reddy’s Laboratories Ltd (NYSE:RDY).

Institutional Ownership by Quarter for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.